Search Results - "Daizadeh, N. S."

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years by Ferrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., O’Malley, C. D., Wagman, R. B., Libanati, C., Lewiecki, E. M.

“…Summary Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years,…”
Get full text

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study by Papapoulos, S., Lippuner, K., Roux, C., Lin, C. J. F., Kendler, D. L., Lewiecki, E. M., Brandi, M. L., Czerwiński, E., Franek, E., Lakatos, P., Mautalen, C., Minisola, S., Reginster, J. Y., Jensen, S., Daizadeh, N. S., Wang, A., Gavin, M., Libanati, C., Wagman, R. B., Bone, H. G.

“…Summary The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis…”
Get full text

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial by Langdahl, Bente L, Libanati, Cesar, Crittenden, Daria B, Bolognese, Michael A, Brown, Jacques P, Daizadeh, Nadia S, Dokoupilova, Eva, Engelke, Klaus, Finkelstein, Joel S, Genant, Harry K, Goemaere, Stefan, Hyldstrup, Lars, Jodar-Gimeno, Esteban, Keaveny, Tony M, Kendler, David, Lakatos, Peter, Maddox, Judy, Malouf, Jorge, Massari, Fabio E, Molina, Jose Fernando, Ulla, Maria Rosa, Grauer, Andreas

“…Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a…”
Get full text

Extended safety observations from denosumab administration in postmenopausal women from FREEDOM and FREEDOM extension trials by Brown, J. P., Bone, H. G., Chapurlat, R., Libanati, C., Brandi, M. L., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, Jean-Yves, Resch, H., Roman Ivorra, J. A., Roux, C., Daizadeh, N. S., Grauer, A., Cummings, S. R., Papapoulos, S.

Get full text

Safety observations from denosumab long-term extension and cross-over studies in postmenopausal women with osteoporosis by Bone, H. G., Chapurlat, R., Libanati, C., Brandi ML, Brown, J. P., Czerwinski, E., Krieg, M. A., Man, Z., Mellstrom, D., Radominski, S. C., Reginster, Jean-Yves, Resch, H., Roman Ivorra, J. A., Roux, Ch, Daizadeh, N. S., Grauer, A., Cummings, S. R., Papapoulos, S.

Get full text

Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the freedom extension by Papapoulos, S, Roux, C, Bone, HG, Dakin, P, Czerwinski, E, Frey, D, Kendler, D, Lewiecki, EM, Malouf, J, Mellström, D, Reginster, Jean-Yves, Resch, H, Daizadeh, NS, Wang, A, Gavin, M, Wagman, RB, Brandi, ML

Get full text

Percentage of women achieving non-osteoporotic BMD T-scores at the lumbar spine (LS) and total hip (TH) during up to 8 years of Denosumab (Dmab) treatment by Ferrari, S, Libanati, C, Lin, CJF, Adami, S, Brown, JP, Cosman, F, Czerwinski, E, De Gregorio, LH, Malouf, J, Reginster, Jean-Yves, Daizadeh, NS, Wang, A, Wagman, RB, Lewiecki, EM, Cummings, S

Get full text

Denosumab treatment of postmenopausal women with osteoporosis for 6 years : results from the first 3 years of the freedom extension by Papapoulos, S, Brown, JP, Chapurlat, R, Franchimont, N, Brandi, ML, Czerwinski, E, Krieg, MA, Man, Z, Mellström, D, Radominski, SC, Reginster, Jean-Yves, Resch, H, Roman, JA, Roux, C, Daizadeh, NS, Geller, ML, Smith, S, Wagman, RB, Cummings, SR, Bone, HG

Get full text